L. P. Oliveira, C. P. Vieira, F. Guerra, Marcos dos Santos Almeida, E. Pimentel
{"title":"他汀类药物治疗和肌腱疾病","authors":"L. P. Oliveira, C. P. Vieira, F. Guerra, Marcos dos Santos Almeida, E. Pimentel","doi":"10.4172/2153-0637.1000E115","DOIUrl":null,"url":null,"abstract":"The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is an enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, a precursor of cholesterol. This enzyme is a target for pharmacological intervention since it acts on cholesterol biosynthesis. At the cellular level, statins inhibit the conversion of HMG-CoA to mevalonic acid, and as a result, inhibit cholesterol synthesis in the liver [2].","PeriodicalId":89585,"journal":{"name":"Journal of glycomics & lipidomics","volume":"10 1","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2013-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Statin Therapy and Tendon Disorders\",\"authors\":\"L. P. Oliveira, C. P. Vieira, F. Guerra, Marcos dos Santos Almeida, E. Pimentel\",\"doi\":\"10.4172/2153-0637.1000E115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is an enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, a precursor of cholesterol. This enzyme is a target for pharmacological intervention since it acts on cholesterol biosynthesis. At the cellular level, statins inhibit the conversion of HMG-CoA to mevalonic acid, and as a result, inhibit cholesterol synthesis in the liver [2].\",\"PeriodicalId\":89585,\"journal\":{\"name\":\"Journal of glycomics & lipidomics\",\"volume\":\"10 1\",\"pages\":\"1-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of glycomics & lipidomics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2153-0637.1000E115\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of glycomics & lipidomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2153-0637.1000E115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is an enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, a precursor of cholesterol. This enzyme is a target for pharmacological intervention since it acts on cholesterol biosynthesis. At the cellular level, statins inhibit the conversion of HMG-CoA to mevalonic acid, and as a result, inhibit cholesterol synthesis in the liver [2].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
